ArticleJournal of family medicine and primary care2026
Hepatitis B vaccine immunity in healthcare workers: Seroprotection and cellular immune signatures of waning response.
Article in Journal of family medicine and primary care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatitis B virus (HBV) poses a significant occupational hazard for healthcare workers (HCWs), particularly in low and middle-income countries with limited routine postvaccination surveillance. While primary vaccination confers robust protection, immunity may wane over time, and the immunological mechanisms underlying nonresponsiveness remain poorly defined. Methodology: We conducted a cross-sectional study among 119 HCWs at a tertiary care biomedical research institute in India. Participants completed structured questionnaires on HBV vaccination history and underwent serological testing for hepatitis B surface antibodies (anti-HBs). Titers ≥10 mIU/mL were considered protective. A representative subset ( Findings: Among 113 HCWs tested, 61.1% had protective anti-HBs titers. Recent vaccination (<5 years) was strongly associated with seroprotection (OR 9.99, 95% CI 3.45-28.92, Interpretation: Durability of HBV vaccine-induced immunity among HCWs is suboptimal beyond 10 years, with immunophenotypic signatures suggesting cellular correlates of nonresponsiveness. These findings support routine serological monitoring and consideration of booster strategies tailored to immune profile in high-risk occupational groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.